AxoGen Azione

AxoGen EV/FCF

Il EV/FCF (Valore aziendale su flusso di cassa libero) di AxoGen (AXGN) al 19 ago 2026 è -583,89. L'anno precedente, EV/FCF (Valore aziendale su flusso di cassa libero) era 155.791,09 — una variazione del -100,37% (inferiore).

EV/FCF

-583,89

YoY

-100,37%

Ultimo aggiornamento:

EV/FCF (Valore aziendale su flusso di cassa libero) di AxoGen ammonta a 2026 -583,89 . EV/FCF (Valore aziendale su flusso di cassa libero) di AxoGen ammontava a 2025 155.791,09 . Diminuisce del -100,37% inferiore rispetto all'anno precedente.
Access this data via the Eulerpool API

AxoGen Analisi delle Azioni

Cosa fa AxoGen? AxoGen Inc is a US-American company based in Alachua, Florida. The company was founded in 2002 as a spin-off of the Grabowski Laboratory at the University of Florida. The goal of the company is to improve the regeneration of peripheral nerves through innovative products and solutions. AxoGen's business model is based on the development, production, and sale of biomaterial-based products for peripheral nerve regeneration. The company has three product categories: Avance nerve tissue, AxoGuard nerve wraps, and AxoTouch nerve testers. Avance nerve tissue is a proven technology for improving the regeneration of peripheral nerves. It consists of allogeneic nerve tissue from donors that has been prepared and sterilized for transplantation. Avance nerve tissue is used for surgical repair of nerve damage and has proven to be very effective in regenerating peripheral nerves. AxoGuard nerve wraps are silicone gels used for repairing nerve damage. They protect the delicate nerve fibers during the healing process and prevent scar formation. AxoGuard nerve wraps were designed to preserve the structure and function of nerves after surgical repair. AxoTouch nerve testers are devices used to measure nerve function. They are used to monitor and evaluate the integrity and function of peripheral nerves. This system is of great importance for assessing the surgical repair of nerve damage and monitoring the progress of healing. In recent years, AxoGen has experienced significant growth and has become a leading company in the field of peripheral nerve regeneration. The company has offices in the US and Europe and distributes its products worldwide. AxoGen is listed on the NASDAQ stock exchange and has a market capitalization of approximately $2.3 billion. AxoGen has made significant progress in recent years and has achieved several important milestones. In 2012, the company received approval from the US Food and Drug Administration (FDA) for the use of Avance nerve tissue for surgical repair of nerve damage. In 2014, AxoGen received CE marking for Avance nerve tissue and AxoGuard nerve wraps, thereby obtaining approval for the European market. AxoGen is continuously working on the development of new products and solutions to improve nerve regeneration. The company has a strong scientific foundation and is heavily involved in research. AxoGen also collaborates with leading scientists and clinics to improve its products and develop new applications. In summary, AxoGen is an innovative company specializing in the development and production of biomaterial-based products for peripheral nerve regeneration. The company has become a market leader in recent years and operates worldwide. AxoGen has brought proven technologies and products to the market that help improve nerve regeneration and enhance patients' quality of life. AxoGen è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su AxoGen azioni

EV/FCF (Valore aziendale su flusso di cassa libero) di AxoGen è -583,89 nel 2026.

Il EV/FCF (Valore aziendale su flusso di cassa libero) di AxoGen è passato da 155.791,09 a -583,89, con una variazione del -100,37 %. Il valore è inferiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del AxoGen di EV/FCF (Valore aziendale su flusso di cassa libero) dal 2006, con valori annuali, grafici e analisi dettagliate.

Il rapporto EV/FCF misura il valore aziendale rispetto al flusso di cassa libero. Cattura la vera capacità di generazione di cassa di un'azienda.

Per valutare di EV/FCF (Valore aziendale su flusso di cassa libero), è essenziale confrontarlo con i competitor nello stesso settore e industria. Su Eulerpool puoi trovare confronti diretti con l'industria per EV/FCF (Valore aziendale su flusso di cassa libero).

Un 'buono' varia a seconda del settore e della fase di sviluppo dell'azienda. Su Eulerpool puoi confrontare AxoGen di EV/FCF (Valore aziendale su flusso di cassa libero) con i competitor del settore e la media industriale per valutare se è attraente.

Access this data via the Eulerpool API

Valutazione — AxoGen

Tutte le Metriche Finanziarie — AxoGen